루카파립
|
|
루카파립 속성
- 녹는점
- 187 - 189°C
- 끓는 점
- 625.2±55.0 °C(Predicted)
- 밀도
- 1.281
- 저장 조건
- 2-8°C(protect from light)
- 용해도
- DMSO(약간 용해됨), 메탄올(약간 용해됨)
- 물리적 상태
- 노란색 고체.
- 산도 계수 (pKa)
- 14.10±0.20(Predicted)
- 색상
- 연한 노란색에서 노란색까지
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
| 그림문자(GHS): |
|
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 신호 어: | Warning | ||||||||||||||
| 유해·위험 문구: |
|
||||||||||||||
| 예방조치문구: |
|
루카파립 C화학적 특성, 용도, 생산
개요
Rucaparib was approved in the US as an oral treatment for advanced ovarian cancer. Development of rucaparib began with collaborations between Cancer Research UK and Agouron Pharmaceuticals (later acquired by Pfizer). Global development rights for rucaparib were ultimately granted to Clovis Oncology via a licensing agreement from Pfizer. To qualify for treatment with rucaparib monotherapy, patients must demonstrate deleterious breast cancer (BRCA) mutation (germline and/or somatic)- associated advanced ovarian cancer and also must have previously been treated with two or more chemotherapy regimens. Rucaparib functions as a small molecule poly(ADPribose) polymerase (PARP) inhibitor, which plays an important role in DNA repair. This newly approved drug displays nanomolar potency against PARP-1, -2, and -3 enzymes, which translates into improved efficacy over alternative therapies such as olaparib or niraparib. Furthermore, rucaparib is also known to cause vasodilation, which is thought to induce tumor perfusion and increased accumulation of the drug in cancer cells. Although rucaparib shows higher cytotoxicity in cancer cells with mutation of BRCA1/2 genes and other DNA repair genes, reduced tumor growth was observed in mouse xenograft models of human cancers with and without BRCA mutations.Rucaparib is also being pursued as a treatment for breast cancer and has displayed promising initial results in trials for pancreatic cancer.용도
Rucaparib is PARP1 inhibitor. It can be used in biological study of chemical screening to identify drugs that enhance or mitigate cellular responses to antibody-toxin fusion proteins using human B cell precursor leukemia cells and cervical adenocarcinoma cells.루카파립 준비 용품 및 원자재
원자재
methyl (4-(8-fluoro-1-oxo-2,3,4,6-tetrahydro-1H-azepino[5,4,3-cd]indol-5-yl)benzyl)(methyl)carbamate
8-fluoro-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one
(4-BROMOBENZYL)메틸아민
준비 용품
루카파립 공급 업체
글로벌( 196)공급 업체
| 공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
|---|---|---|---|---|---|
| Zhejiang ZETian Fine Chemicals Co. LTD | +8618957127338 |
stella@zetchem.com | China | 2136 | 58 |
| Capot Chemical Co.,Ltd. | 571-85586718 +8613336195806 |
sales@capotchem.com | China | 29798 | 60 |
| Shanghai Daken Advanced Materials Co.,Ltd | +86-371-66670886 |
info@dakenam.com | China | 18628 | 58 |
| Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 |
info@tianfuchem.com | China | 21663 | 55 |
| Hangzhou FandaChem Co.,Ltd. | 008657128800458; +8615858145714 |
fandachem@gmail.com | China | 9284 | 55 |
| Nanjing ChemLin Chemical Industry Co., Ltd. | 025-83697070 |
product@chemlin.com.cn | CHINA | 3012 | 60 |
| Shanghai Yingrui Biopharma Co., Ltd. | +86-21-33585366 - 03@ |
sales03@shyrchem.com | CHINA | 738 | 60 |
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 |
ivan@atkchemical.com | China | 32836 | 60 |
| career henan chemical co | +86-0371-86658258 +8613203830695 |
sales@coreychem.com | China | 29888 | 58 |
| Jinan Shengqi pharmaceutical Co,Ltd | 86+18663751872 |
christine@shengqipharm.com | CHINA | 491 | 58 |
루카파립 관련 검색:
Rucaparib Camsylate
Ruxolitinib phosphate
Ruxolitinib
1,5,7,8-TETRAHYDRO-2-METHYL-4H-THIOPYRANO[4,3-D]PYRIMIDIN-4-ONE
PJ-34
PF-01367338
Benzamide
Minocycline hydrochloride
1,5-ISOQUINOLINEDIOL
1(2H)-Isoquinolinone, 5-aMino-, Monohydrochloride
4-AMINO-1,8-NAPHTHALIMIDE
3-Aminobenzamide
NU1025
4-Hydroxyquinazoline
DPQ
ABT-888
3-(4-CHLORO-PHENYL)-QUINOXALINE-5-CARBOXYLIC ACID AMIDE
TIQ-A